1. Direct Comparison of (N)-Methanocarba and Ribose-Containing 2-Arylalkynyladenosine Derivatives as A3 Receptor Agonists
   Dilip K. Tosh et al, 2020, ACS Med. Chem. Lett. CrossRef
2. Design and in vivo activity of A3 adenosine receptor agonist prodrugs
   R. Rama Suresh et al, 2020, Purinergic Signalling CrossRef
3. Immune-Mediated Mechanisms in Cofactor-Dependent Food Allergy and Anaphylaxis: Effect of Cofactors in Basophils and Mast Cells
   Rosa Muñoz-Cano et al, 2021, Front. Immunol. CrossRef
4. Exercise in mice ameliorates high-fat diet-induced nonalcoholic fatty liver disease by lowering HMGCS2
   Xiaoli Qian et al, 2021, Aging CrossRef
5. Purinergic Signaling in Liver Pathophysiology.
   Shanu Jain et al, 2021, Front Endocrinol (Lausanne) CrossRef
6. An Efficient Model of Non-alcoholic Fatty Liver Disease (NAFLD) Versus Current Experimental Models: Effects of Fructose, Fat, and Carbon Tetrachloride on NAFLD
   Zahra Eslami et al, 2021, Hepat Mon CrossRef
7. Selective A3 Adenosine Receptor Antagonist Radioligand for Human and Rodent Species
   R. Rama Suresh et al, 2022, ACS Med. Chem. Lett. CrossRef
8. ATP Secretion and Metabolism in Regulating Pancreatic Beta Cell Functions and Hepatic Glycolipid Metabolism
   Jing Li et al, 2022, Front. Physiol. CrossRef
9. Integrins as a drug target in liver fibrosis
   Syedia R. Rahman et al, 2022, Liver International CrossRef
10. Characterization of Dual-Acting A3 Adenosine Receptor Positive Allosteric Modulators That Preferentially Enhance Adenosine-Induced Gαi3 and GαoA Isoprotein Activation
    Courtney L. Fisher et al, 2022, ACS Pharmacol. Transl. Sci. CrossRef
11. Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease
    Yajie Fu et al, 2022, Front. Pharmacol. CrossRef
12. Targeting the A3 adenosine receptor to treat hepatocellular carcinoma: anti-cancer and hepatoprotective effects
    Pnina Fishman et al, 2023, Purinergic Signalling CrossRef
13. Research Progress on the Effect of Autophagy and Exosomes on Liver Fibrosis
    Yikuan Du et al, 2024, CSCR CrossRef
14. Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
    Michail Kokkorakis et al, 2024, Pharmacol Rev CrossRef
15. 2-Substituted (N)-Methanocarba A3 Adenosine Receptor Agonists: In Silico, In Vitro, and In Vivo Characterization
    Dilip K. Tosh et al, 2024, ACS Pharmacol. Transl. Sci. CrossRef
16. The different effects of four adenosine receptors in liver fibrosis
    Lan Yang et al, 2024, Front. Pharmacol. CrossRef